Docetaxel impurity 1, identified by the CAS number 1095548-07-4, is a chemical compound associated with the pharmaceutical agent docetaxel, which is used primarily in cancer treatment. As an impurity, it may arise during the synthesis or degradation of docetaxel and can affect the purity and efficacy of the final product. The characteristics of this impurity typically include its molecular structure, which is closely related to that of docetaxel, and its potential biological activity, which may differ from the parent compound. Impurities like this can influence the pharmacokinetics and pharmacodynamics of the drug, making their identification and quantification crucial in pharmaceutical development and quality control. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are often employed to characterize such impurities. Understanding the properties and behavior of docetaxel impurity 1 is essential for ensuring the safety and effectiveness of docetaxel formulations in clinical use.

Docetaxel impurity1

1095548-07-4: Docetaxel impurity 1, identified by the CAS number 1095548-07-4, is a chemical compound associated with the pharmaceutical agent docetaxel, which is used primarily in cancer treatment. As an impurity, it may arise during the synthesis or degradation of docetaxel and can affect the purity and efficacy of the final product. The characteristics of this impurity typically include its molecular structure, which is closely related to that of docetaxel, and its potential biological activity, which may differ from the parent compound. Impurities like this can influence the pharmacokinetics and pharmacodynamics of the drug, making their identification and quantification crucial in pharmaceutical development and quality control. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are often employed to characterize such impurities. Understanding the properties and behavior of docetaxel impurity 1 is essential for ensuring the safety and effectiveness of docetaxel formulations in clinical use.

(1S,3R,4S,4aR,5R,7R,8R,11R,12aS)-4-(Acetoxymethyl)-8-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,3,4,7,11-pentahydroxy-9,12a,13,13-tetramethyl-12-oxo-1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-6,10-methanobenzo[10]annulen-5-yl Benzoate

CAS 1095548-07-4

Docetaxel impurity1

(1S,3R,4S,4aR,5R,7R,8R,11R,12aS)-4-(Acetoxymethyl)-8-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,3,4,7,11-pentahydroxy-9,12a,13,13-tetramethyl-12-oxo-1,2,3,4,4a,5,6,7,8,11,12,12a-dodecahydro-6,10-methanobenzo[10]annulen-5-yl Benzoate

Ref: ST-EA-CP-D32067